Equities

Alpha Tau Medical Ltd

DRTS:NAQ

Alpha Tau Medical Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.83
  • Today's Change0.16 / 5.99%
  • Shares traded113.33k
  • 1 Year change-15.52%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.

  • Revenue in USD (TTM)0.00
  • Net income in USD-29.16m
  • Incorporated2015
  • Employees121.00
  • Location
    Alpha Tau Medical LtdKiryat Hamada 5JERUSALEM 9777605IsraelISR
  • Phone+972 35774115
  • Fax+972 36182477
  • Websitehttps://www.alphatau.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fennec Pharmaceuticals Inc44.95m2.84m190.78m36.00192.5163.3167.084.240.03660.03661.620.11120.98781.157.52--6.25-73.437.37-84.3296.19--6.33-383.286.721.840.9087--1,284.50--32.34------
P3 Health Partners Inc1.35bn-67.27m191.09m400.00--0.4924--0.1413-0.5855-0.585511.861.231.57--11.403,381,965.00-21.31---90.11--1.590.1781-13.57-56.93---10.050.2368--20.6770.5878.61---11.20--
Veru Inc13.48m-35.82m193.23m189.00--4.27--14.34-0.3465-0.34650.12670.30890.18981.423.8671,318.68-50.43-42.91-76.84-54.4134.1372.41-265.74-104.964.22--0.177---58.590.5394-10.84--67.39--
Trevi Therapeutics Inc0.00-33.57m195.11m25.00--2.64-----0.338-0.3380.001.050.00----0.00-34.47-47.39-38.08-54.41------------0.0017------0.2984---2.81--
bluebird bio Inc21.73m-91.17m196.07m323.00--0.4954--9.02-0.7446-0.74460.21392.080.0383----67,263.16-16.08-33.02-21.50-37.14-10.0819.44-419.62-4,044.311.42--0.00---1.77-36.7152.62---26.66--
Atossa Therapeutics Inc0.00-29.69m196.73m10.00--2.30-----0.2359-0.23590.000.68330.00----0.00-28.65-29.97-29.84-32.55------------0.00-------11.62---33.90--
Alpha Tau Medical Ltd0.00-29.16m197.17m121.00--2.33-----0.4203-0.42030.001.210.00----0.00-25.63---26.99--------------0.0623------13.64------
Capricor Therapeutics Inc27.10m-24.31m197.23m101.00--10.63--7.28-0.8755-0.87550.95740.58340.5246--59.13268,299.50-47.07-54.12-122.20-75.13-----89.72-316.25----0.1548--886.8172.0223.20--45.27--
Elevation Oncology Inc0.00-39.35m197.24m29.00--2.46-----1.03-1.030.001.470.00----0.00-42.35---46.30-------------12.500.2889------51.93------
Puma Biotechnology Inc226.63m15.38m197.54m185.0012.723.877.340.87160.32190.32194.741.061.1010.958.131,225,016.007.49-12.2111.65-20.5373.4478.786.78-11.791.382.570.6624--3.34-1.251,079,450.00--83.41--
Zevra Therapeutics Inc28.01m-50.90m197.97m65.00--4.05--7.07-1.34-1.340.75131.170.2172--3.47430,876.90-39.48-32.11-47.94-39.8951.11---181.75-128.42----0.4929--170.26---72.00--69.75--
CytoDyn Inc0.00-51.69m198.67m12.00---------0.055-0.0550.00-0.12060.00----0.00-414.98-259.98-----------235,303.80---0.88-----100.00--62.14------
CervoMed Inc8.08m-4.15m198.83m8.0047.1227.86--24.600.51130.51131.740.86480.6124----1,010,531.00-31.45-53.67-38.42-58.89-----51.36-949.54----0.00------86.07------
Omeros Corp0.00-179.09m199.91m198.00---------2.90-1.970.00-1.230.00----0.00-35.90-55.51-44.81-70.10-----------5.391.19------3.91---5.56--
Galectin Therapeutics Inc0.00-44.78m199.95m14.00---------0.7373-0.73730.00-1.140.00----0.00-177.94-92.08-373.85-121.97-----------10.247.25-------15.26------
Lineage Cell Therapeutics Inc8.00m-23.66m203.90m75.00--2.82--25.48-0.1344-0.13440.04550.38360.0722--57.16106,706.70-21.32-19.53-24.82-22.5991.8889.13-295.30-370.88----0.0018---39.1612.3918.22---27.16--
Data as of May 17 2024. Currency figures normalised to Alpha Tau Medical Ltd's reporting currency: US Dollar USD

Institutional shareholders

2.29%Per cent of shares held by top holders
HolderShares% Held
Levin Capital Strategies LPas of 31 Mar 2024338.76k0.49%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024306.49k0.44%
HoyleCohen LLCas of 31 Mar 2024269.09k0.39%
Corbin Capital Partners LPas of 31 Mar 2024260.11k0.37%
HighTower Advisors LLCas of 31 Mar 2024212.51k0.31%
Private Advisor Group LLCas of 31 Mar 202458.43k0.08%
Satovsky Asset Management LLCas of 31 Mar 202448.59k0.07%
Mariner LLCas of 31 Mar 202438.58k0.06%
Geode Capital Management LLCas of 31 Mar 202435.72k0.05%
Kovitz Investment Group Partners LLCas of 31 Mar 202429.72k0.04%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.